An AstraZeneca spokesperson told Sky News: "Following discussions with the current government, we are no longer pursuing our planned investment at Speke. "Several factors have influenced this ...
was S$780 now S$465 for your first year Make up your own mind. Build robust opinions on the FT's trusted journalism. Offer available until 27 February 2025.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback